Hutchmed to Present New Savolitinib Cancer Trial Data
The November 5 webcast will provide clinical insights into the use of savolitinib combined with Tagrisso for cancer patients.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies provide full transparency regarding clinical trial data results?
Hutchmed will host a webcast on November 5, 2026, to discuss clinical trial data for the cancer drug savolitinib. The update follows positive results reported in August 2026 from the international SAFFRON phase III trial.
Why it matters
Understanding clinical data for combination therapies like savolitinib and Tagrisso is essential for patients and clinicians evaluating new lung cancer treatment options. The findings follow trial results released at the 2026 ESMO Congress.
The SAFFRON phase III trial enrolled 338 patients across 29 countries, reporting positive outcomes in progression-free and overall survival in August 2026. The trial selection process utilized high MET level cut-offs identified in the earlier SAVANNAH phase II study.
The players
Hutchmed
A biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies for cancer.
Yi-Long Wu
A professor and clinical researcher specializing in lung cancer treatment and oncology study leadership.
Weiguo Su
A researcher and executive providing insight into clinical drug development and oncology pipeline progress.
The details
Savolitinib is a targeted therapy designed to address MET overexpression or amplification, a specific genetic driver in some lung cancers. The drug is administered in combination with Tagrisso to overcome resistance patterns, with the SANOVO study randomizing 326 patients to compare the efficacy of this combination against a placebo. This approach targets specific molecular pathways to stop tumor cell signaling.
Timeline
August 2026: The SAFFRON phase III trial reported positive results.
November 5, 2026: Hutchmed hosts an expert insights webcast.
Health Landscape
This development reflects the ongoing shift toward precision oncology, where drug combinations are tailored to specific genetic mutations like MET amplification. It follows the data presented at the ESMO Congress 2026.
Patients and caregivers interested in new lung cancer treatment combinations should discuss the relevance of MET-targeted therapies with an oncologist. Tracking clinical trial updates is a helpful way to stay informed about potential future treatment options.
The takeaway
Savolitinib, known as Orpathys in China, is currently being evaluated for its role in managing specific lung cancer mutations. Discuss current treatment standards and the availability of clinical trials with your physician if you are managing a lung cancer diagnosis.
Further reading
Learn more about the latest research in this area by visiting our Cancer section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you trust that pharmaceutical companies provide full transparency regarding clinical trial data results?
